A Pechmann, M Behrens, K Dörnbrack, A Tassoni… - Brain, 2023 - academic.oup.com
Abstract 5q-associated spinal muscular atrophy is a rare neuromuscular disorder with the leading symptom of a proximal muscle weakness. Three different drugs have been …
D Horgan, M Hajduch, M Vrana, J Soderberg… - Healthcare, 2022 - mdpi.com
The May 2022 proposal from the European commission for a 'European health data space'envisages advantages for health from exploiting the growing mass of health data in …
NA Dreyer, CD Mack - Pragmatic and Observational Research, 2023 - Taylor & Francis
Real-world evidence (RWE) is being used to provide information on diverse groups of patients who may be highly impacted by disease but are not typically studied in traditional …
E Wellnhofer - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Recent progress in digital health data recording, advances in computing power, and methodological approaches that extract information from data as artificial intelligence are …
Y Yao, F Yang - Frontiers in Public Health, 2023 - frontiersin.org
In the information age, real-world data-based evidence can help extrapolate and supplement data from randomized controlled trials, which can benefit clinical trials and drug …
MM Nowak, M Niemczyk, M Florczyk… - Journal of Clinical …, 2022 - mdpi.com
Statins are lipid-lowering medications used for the prevention of cardiovascular disease (CVD), but the pleiotropic effects of statins might be beneficial in other chronic diseases. This …
J Dibato, O Montvida, WH Polonsky… - The Primary Care …, 2022 - psychiatrist.com
Objective: To evaluate the temporal trend in young adult depression, prescription patterns of first-and second-line antidepressants, and factors influencing therapy intensification for …
В современном мире область данных, собираемых в условиях реальной клинической практики (РКП; англ. real world data, RWD), а также доказательств, получаемых путем …
R Jandhyala - Journal of Pharmaceutical Policy and Practice, 2022 - Springer
Background Despite calls for the use of additional real-world evidence (RWE) during drug development, rates of inclusion at the regulatory stage remain low. The medicine adoption …